Celltrion's Stelara biosimilar recommended for EU approval
Celltrion said Monday that CT-P43, its ustekinumab biosimilar referencing Stelara, received an approval recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Stelara is Janssen's top-selling drug for psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The global market for ustekinumab last year was estimated at around $20 billion, Celltrion added. “CHMP’s recommendation plays a decisive role in the EMA&
July 1, 2024